

Special Issue

Novel Inhibitors: Design, Synthesis, Biological Activities and Modelling Studies

Message from the Guest Editors

Altering enzyme activity has profound biological and medicinal effects; thus, enzyme inhibitors enable the selective inhibition of essential pathogenic enzymes (acting as antibiotics, antivirals, or antiparasitic agents) or of aberrant human enzymes (correcting for a pathological condition). Enzyme inhibitors may bind irreversibly (through covalent bonding) or reversibly (through non-covalent bonding), but in either case, drawbacks to the inherent mechanism of action must be considered, adding additional barriers to the development of viable inhibitors. This Special Issue pays homage to the drug discovery progress of inhibitors, which requires exceptional dedication, skill, and creativity. For this Special Issue, we welcome papers that highlight the development and biological evaluation of organic compounds (this can be addressed from several sub-disciplines, including medicinal chemistry, total synthesis, natural product chemistry, and computational chemistry).

Guest Editors

Dr. Hari Krishna Namballa

Department of Chemistry, Hunter College, City University of New York,
695 Park Avenue, New York, NY 10065, USA

Dr. Velma Ganga Reddy

College of Pharmacy, The University of Arizona, Tucson, AZ 85721, USA

Deadline for manuscript submissions

30 September 2025



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/202495

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).